Vaxxinity announces positive topline pivotal phase 3 covid-19 booster data for ub-612

Vaxxinity's next-generation covid-19 booster candidate ub-612 achieves primary and key secondary immunogenicity endpoints in a pivotal head-to-head heterologous booster trial against three authorized vaccine platforms: mrna (pfizer-biontech's bnt162b2), adenovirus vector (astrazeneca's chadox1-s), and inactivated virus (sinopharm's bibp)
VAXX Ratings Summary
VAXX Quant Ranking